

# DirectConnect

Inside Yale Cancer Center

**August 18, 2023**

Dear Colleagues,

Many of us are working furiously on the submission of our Cancer Center Support Grant. This grant, which we have held continuously since 1974, allows us to call YCC and Smilow a “NCI-designated Comprehensive Cancer Center.” Working on a project this large is always arduous, sometimes overwhelming, occasionally tedious, and INCREDIBLY valuable. As we assemble the grant, we think about who we are, what we want to be, and how we will get there. It is a great opportunity for us to exchange ideas, think through possibilities, and lay out our plans in writing. We have challenged one another and asked a series of questions: What should we do to increase our scientific output? How do we improve our patient care? What steps must be taken to diversify our staff? And from a cancer standpoint, what are the critical needs of the community we serve?

I believe we have tremendous strengths here at Yale. There is, however, always room for improvement. Our goals are lofty. We want to have the scientific impact that will change the face of cancer, and at the same time, we want to be the very best place to receive cancer care. And we want to build a center where everyone is delighted to come to work each day. In truth, these two pillars of our mission are complementary—like a hand and glove. It is the relentless pursuit of these goals that makes YCC and Smilow so special. I think we are taking real steps towards this vision, and we have the team to make it a reality.

Please enjoy the last few weeks of the summer. Signing off until September.

Eric

## Announcements

### Dr. David Schoenfeld joins the Skin and Kidney Cancer Program

The Skin and Kidney Cancer Program at Smilow Cancer Hospital and Yale Cancer Center is pleased to welcome David Schoenfeld, MD, PhD. Dr. Schoenfeld is an

Instructor of Medicine (Medical Oncology) and cares

### Eric P. Winer, MD

Director, Yale Cancer Center  
Physician-in-Chief, Smilow Cancer Network

Yale  
NewHaven  
Health  
Smilow Cancer  
Hospital

Yale **CANCER** CENTER  
A Comprehensive Cancer Center Designated  
by the National Cancer Institute

## News Center



**Smilow Cancer Hospital Recognized  
Among the Nation's Best for Cancer Care  
2023-2024**



[Read More](#)

[YouTube Says It's Now Removing Videos](#)

(Medical Oncology) and cares for patients with melanoma and advanced skin and kidney cancers at Smilow Cancer Hospital in New Haven. He received his medical degree and a PhD in Cellular, Molecular, and Biomedical Studies from Columbia University as part of the Medical Scientist Training Program. He then joined the Physician-scientist Training Program at Yale where he completed his residency and fellowship training.



Dr. Schoenfeld conducts bench-to-bedside cancer immunology research and he is helping develop novel cancer therapies. He is investigating the tumor immune microenvironment and testing new immunomodulatory drugs and combinations in preclinical models, with the goal of bringing new treatments to patients by conducting early phase clinical trials. His research has been supported in part by the T32 Yale Cancer Center-Advanced Training Program for Physician-scientists.

### **Dr. Adriana Kahn joins Center for Breast Cancer**

Adriana Kahn, MD, is an Assistant Professor of Medicine (Medical Oncology) and cares for patients as part of the Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center in New Haven. Dr. Kahn completed a fellowship in Medical Oncology at Yale School of Medicine, and her residency at the University of Connecticut. She also completed a fellowship in breast cancer in Canada and a residency and medical oncology fellowship at the Universidade de Sao Paulo, Brazil. She received her medical degree from the Universidade Federal da Bahia, Brazil.



Dr. Kahn's research focuses on breast cancer and drug development. She was awarded the 2023 Robert A. Winn Diversity in Clinical Trials Career Development Award from the American Association of Cancer Research Career (AACR), as well as the 2023 Young Investigator Award from the American Society of Clinical Oncology (ASCO) for her ongoing work. She is

### **YouTube Says It's Now Removing Videos Promoting Cancer Misinformation**



[Listen Now](#)

---


### **Get Comfy During Breast Cancer: Feel-Good Clothes, Wigs, Scarves**



[Read More](#)

---

### **Study Shows Promise of Immunotherapy Treatment for Penile Cancer**



[Read More](#)

---

### **Study: Low-Risk Long-Term Cancer Survivors Much More Likely to Die of Noncancer Causes**



the author of numerous peer-reviewed publications and poster presentations at national and international conferences. In addition, she is leading investigator-initiated clinical trials as principal investigator of ongoing clinical trials at Yale Cancer Center.

## Volunteer for Closer to Free!



The Closer to Free Ride cannot happen without the dedication and support of hundreds of volunteers. If you're not pedaling to support Smilow Cancer Hospital and Yale Cancer Center on September 9, join us as a volunteer and share your energy and enthusiasm with our community.

We are in need of volunteers from 6am-6pm at the Yale Bowl. Volunteers receive a CTF Ride volunteer t-shirt, food tickets to use at our Food Truck Festival, lunch out on the route, and two complimentary beverages in the Beer & Wine Garden.

Please reach out to [Kristen Alves](#) for more information.

## ASCO Review

Registration is now open for our Review of Advances in Oncology, Highlights from the ASCO® Annual Meeting 2023. For anyone who was unable to travel to Chicago to attend ASCO in person, and for those who are interested in hearing new advances from Yale Cancer Center, our ASCO Review will provide updates on treatment options; outcomes of clinical trials; and assess the emerging role of immunotherapy, targeted therapies, and antibodies in oncology.

Please join us on Friday, September 29, 2023, at Anthony's Ocean View in New Haven. **Register today.**

## Notables

The laboratory of **David A. Braun, MD, PhD**, Assistant Professor of Medicine (Medical Oncology), Louis Goodman and Alfred Gilman Yale Scholar, and a member of Yale Cancer Center's Cancer Immunology Research Program, has received approximately \$5.75M in federal awards to fund mechanisms of response and resistance to immune therapy in kidney




[Read More](#)

## Study Suggests Breast Cancer Screening for Older Women Carries Risks



[Read More](#)

## Opinion: Cancer Patients Should Never Be Put In This Situation



[Watch Now](#)

## Smilow Cancer Hospital Celebrates Opening of Dedicated Inpatient Sickle Cell Disease Clinic



[Read More](#)

## Researchers Find a Vulnerability in Lung Cancers Resistant to Targeted Therapies



and mechanisms of response and resistance to immune therapy in kidney cancer at Yale Cancer Center. The National Cancer Institute awarded Dr. Braun an **R37 MERIT Award**, which is an extension of an R01 and provides longer term grant funding to particularly meritorious applications from early-stage investigators. In addition, through the Congressionally Directed Medical Research Program (CDMRP) Kidney Cancer Research Program, Dr. Braun has also received an **Idea Development Award**. [Learn more](#)

**Dr. Braun** has joined the leadership of the **Yale Medical Oncology-Hematology Fellowship Program** as the **Associate Program Director for Research**. In this role, he will oversee the development of our physician-scientist trainees and our fellows interested in laboratory-based basic and translational science careers. Dr. Braun's unwavering commitment to the development of young physician-scientist trainees will be invaluable to the program. He's been an advisor and mentor to countless physician-scientist trainees over the years and understands first-hand the unique privileges and challenges that residents and fellows interested in lab-based careers face as they move through their clinical training with the goal of eventually becoming independent investigators.

**Veda Giri, MD**, Division Chief, Clinical Cancer Genetics, Director, Cancer Genetics and Prevention Program, and Director, Early Onset Cancer Program, received a grant from **Bakes for Breast Cancer** to fund her PROSPER study, which focuses on early onset cancer. Bakes for Breast Cancer funds dedicated oncologists at the earliest stages of clinical research. [Learn more](#)


**David Carlson, PhD, DABR, FAAPM**, Professor of Therapeutic Radiology, Vice Chair for Physics, Therapeutic Radiology, and Director of Medical Physics, has been named a **Fellow of the American Society for Radiation Oncology** (ASTRO). Dr. Carlson will receive his FASTRO designation at an awards ceremony in San Diego on October 3rd during ASTRO's 65th Annual Meeting.

**Seth Herzon, PhD**, Milton Harris '29 Ph.D. Professor of Chemistry, Professor of Pharmacology and of Therapeutic Radiology, and a member of Yale Cancer Center's Developmental Therapeutics Research Program, is the inaugural winner of the **A.V. Rama Rao Award**, given by the Council of the Chemical Research Society of India (CRSI). Dr. Herzon will accept the award next year during a CRSI National Symposia in Chemistry in India, where he will also deliver a lecture.

In addition, **Dr. Herzon** has received an **R01** in collaboration with **Ranjit Bindra, MD, PhD**, Harvey and Kate Cushing Professor of Therapeutic Radiology and Professor of Pathology; Vice Chair for Translational Research, Therapeutic Radiology; Scientific Director, Chênevert Family Brain Tumor Center at Smilow Cancer Hospital and Yale Cancer Center, to support their research, "Novel therapeutics for the targeted eradication of DDR-defective tumors."

**Stephanie Halene, PhD, Dr Med**, has been appointed **Arthur H. and Isabel Bunker Professor of Medicine (Hematology)** and Professor of Pathology. Dr. Halene is also Chief of Hematology and Director of the DeLuca Center for Innovation in Hematology Research.


**Kurt Schalper, MD, PhD**, Associate Professor of Pathology, Director of the



[Read More](#)

---

### Method Allows New Insights into Interplay Between Immune System and Tumors



[Read More](#)

---

### Researchers Develop a New Way to Classify HPV-Associated Head and Neck Cancers



[Read More](#)

---

### Study: Big Benefits from Oncology Comanagement



Translational Immunology Laboratory, and a member of Yale Cancer Center's Cancer Immunology Research Program, was the recipient of the **Best Mentor Award** at the **2023 Methods in Clinical Cancer Research Workshop** last month.

Congratulations to **Layla Van Doren, MD, MBA**, named our **2023 Forget Scholar**. The Forget Scholar award was established in 2015 in honor of Dr. Bernard Forget, renowned hematologist and scientist. The annual award is given to a deserving individual who is transitioning from their fellowship to an academic career in hematology. Dr. Van Doren is an Assistant Professor of Medicine (Hematology) and cares for patients with sickle cell disease and patients with bleeding and clotting disorders at Smilow Cancer Hospital.

In addition, **Dr. Van Doren** has received an **Education Research Grant** from the **Yale Department of Internal Medicine** to study "Exploring providers' preferences for education on the management of patients with sickle cell disease (SCD)." The grant will support the first of a two-part study, which aims to understand the educational demands of providers caring for patients with sickle cell disease using qualitative and quantitative methods.

**Barbara Burtness, MD**, Professor of Medicine (Medical Oncology), Chief of Translational Research, and Co-Director of the Developmental Therapeutics Research Program, recently presented during the Plenary session at the **AACR/AHNS Head and Neck Cancer Conference** in Montreal on "Immunotherapy for HPV-Associated Oropharynx Cancer." Dr. Burtness also presented at the **AHNS International Meeting** in the Milton J. Dance Symposium on "Treatment Optimization for Early Stage HPV-Associated Oropharynx Cancer."

**Sarah Goldberg, MD, MPH**, Associate Professor of Medicine (Medical Oncology) and Research Director of the Center for Thoracic Cancers, Co-Chaired the **2023 SNO/ASCO CNS Cancer Conference** focused on accelerating therapeutic discovery and advancing care of patients with primary and metastatic CNS malignancies last week in San Francisco. **Don Nguyen, PhD, BS**, Associate Professor of Pathology and Medicine (Medical Oncology) and Co-Director of Yale Cancer Center's Signal Pathology Research Program, provided the keynote address on "Adaptive Mechanisms of Brain Metastasis and Therapeutic Response in Lung Cancer." **Roy S. Herbst, MD, PhD**, Deputy Director of Yale Cancer Center and Assistant Dean for Translational Research, led a Brain Metastases Think Tank discussion at the meeting.

The **Center for Gastrointestinal Cancers (CGIC)** has selected three Yale Cancer Center teams for funding through its **2023-24 CGIC Seed Grant Program**. The intramural grant program is designed to spur interdisciplinary team-based basic, translational, clinical, or population health research in GI cancers by providing pilot funding to support new or existing projects in early

stages. Congratulations to the awardees:

- **Michael Chiorazzi, MD, PhD**, Assistant Professor of Medicine (Medical Oncology) and a member of Yale Cancer Center's Cancer Immunology Research Program, and **Michael Cecchini, MD**, Assistant Professor of Medicine (Medical Oncology), Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers, and a member of Yale Cancer Center's Developmental Therapeutics Research Program: "Identification of Tumor Determinants Leading to Immune Privilege for Colorectal Cancers."


[Read More](#)

**Advances in Particle Therapy - Proton Track-end Counts and Helium Ion Treatment Planning**




[Listen Now](#)

**Yale Scientists Identify Immune Cells Critical for Immunologic Memory for Melanoma**



[Read More](#)

**Yale Scientists Develop a New Approach to Strengthen CAR-T Cell Therapy for Cancer Treatment**



[Read More](#)

**Six Smilow Radiation Oncology Centers Receive Accreditation by the American Society for Radiation Oncology (ASTRO)**

Colorectal Cancer Liver Metastasis"

- **Prajwal Boddu, MBBS**, Associate Research Scientist, Medical Oncology, and **Luisa Escobar-Hoyos, PhD**, Assistant Professor of Therapeutic Radiology and a member of Yale Cancer Center's Radiobiology and Genome Integrity Research Program: "Biology of Splicing Factor Mutations in Pancreatic Ductal Adenocarcinoma (PDAC)"
- **Carrie Lucas, PhD**, Associate Professor of Immunobiology and a member of Yale Cancer Center's Cancer Immunology Research Program, and **Michael Cecchini, MD**: "Applying insights from monogenic autoinflammation to anti-tumor immunity in colorectal cancer"

**Jacqueline Gaddy, MD, MSc, MSCR**, Assistant Professor of Medicine (Medical Oncology), Deputy Director of the Diversity Enhancement Program in Oncology, and a member of Yale Cancer Center's Cancer Prevention and Control Research Program, has been selected to participate in the **Robert A. Winn Diversity in Clinical Trials: Career Development Award (Winn CDA)** for early-stage investigator physicians. The Winn CDA aims to develop a new generation of clinical trialists with the additional knowledge, skills, and competencies to effectively engage with communities to foster active community participation in clinical research.

**George Goshua, MD, MSc**, Assistant Professor of Medicine (Hematology) within the Classical Hematology Program, has been invited to join the **Annals of Internal Medicine Editorial Board** for a three-year term, effective July 1, 2023.

Congratulations to the following Yale Cancer Center Members who have been awarded a **2023 YCC Pilot Award!** The 2023 YCC Pilot grants support areas of innovative cancer research from all six YCC Research Programs.

- **Daniel Boffa, MD**, Professor of Surgery (Thoracic Surgery), Division Chief, Thoracic Surgery, Clinical Director, Center for Thoracic Cancers, and a member of Yale Cancer Center's Radiobiology and Genome Integrity Research Program, "Data Linkage to Enhance Representativeness and Equity of Cancer Care – Pilot in the State of Connecticut."
- **Andres Hidalgo, PhD**, Professor of Immunobiology and a member of Yale Cancer Center's Cancer Immunology Research Program, "Understanding the origin of tumor-supportive neutrophils."
- **Yannick Jacob, PhD**, Associate Professor of Molecular, Cellular and Developmental Biology and a member of Yale Cancer Center's Genomics, Genetics, and Epigenetics Research Program, "The mechanism of genome instability in pediatric brain tumors caused by H3K27M."
- **Diane Krause, MD, PhD**, Anthony N. Brady Professor of Laboratory Medicine, Professor of Pathology, and a member of Yale Cancer Center's Genomics, Genetics, and Epigenetics Research Program, "Novel Inducible Mouse Model of AMKL."
- **Smita Krishnaswamy, PhD**, Associate Professor of Genetics and of Computer Science and a member of Yale Cancer Center's Cancer Immunology Research Program, "Mapping and Modulating Dynamic Transitions across the Cancer Plasticity Landscape."
- **Shuangge Steven Ma, PhD**, Chair of the Department of Biostatistics, Professor of Biostatistics, Director of the Biostatistics and Bioinformatics Shared Resource, and a member of Yale Cancer Center's Cancer Prevention and Control Research Program, "Cancer omics modeling with statistically principled deep learning."
- **Michael Mak, PhD**, Assistant Professor of Biomedical Engineering and a member of Yale Cancer Center's Cancer Signaling Networks Research Program, "Computational and Biomimetic Approaches for Liver Cancer Progression and Resistance."
- **Jiangbing Zhou, PhD, FAHA**, Associate Professor of Neurosurgery



YaleNewHavenHealth  
Smilow Cancer Hospital

Yale CANCER CENTER  
A Comprehensive Cancer Center Designated  
by the National Cancer Institute

[Read More](#)



Congratulations to the 2023 Susan D. Flynn Oncology Nursing Fellows on the completion of their summer fellowships!

The Fellows completed 8-week rotations featuring a comprehensive clinical experience in oncology nursing, plus exposure to "best practices" and expert training in compassionate care, including palliative care. Direct observational and learning experiences included exposure to ambulatory oncology nursing, acute care medical and surgical oncology nursing, infusion services, and more.



[Read More](#)

Recently on Yale Cancer Answers, speech pathologist, John Gerrity, discussed his role in caring for patients after a diagnosis of head and neck cancer and methods of restoring speech. Listen on Connecticut Public Radio or download our podcast from iTunes.







## Employee Profile: Edwin Antunes

Edwin Antunes, Intake Coordinator for the Endocrine Program, has been with Smilow Cancer Hospital since 2021, and has worked in the field of oncology for 10 years. A cancer survivor himself, he has a deeply rooted passion caring for patients with cancer. He is the first point of contact for many patients and introduces them to the process while establishing a relationship he hopes will continue down the road.



“That first encounter can make or break a patient’s first impression, and I take that very seriously,” said Edwin. “It may be my tenth call of the day, but this is their first interaction with their care team and I want to make it as easy of a process as possible. I make it clear from the start that they can reach out to me at any time and that we strive for excellence and try to display that with every encounter.”

As referrals come in, Edwin explains the process. If they are scheduled for an appointment, he makes sure all the necessary documents are collected, explains location and parking information, and answers any questions; anything to reduce anxiety ahead of their first appointment. Even while fielding calls daily, Edwin communicates closely with the other team members. He is an enthusiastic staff member and works well with his team to keep Smilow’s vision of patient-centered care front and center. He remains a point of contact for as long as they need him. “You can’t force kindness,” said Edwin. “I am not just an intake coordinator, but also a care coordinator and I try to spread kindness and joy, because it is tough out there.”

Maria Llanos, Clinical Operations Manager, commented, “I remember my first interview with Edwin; I knew Smilow needed his impeccable patient-centric background. When he accepted the position I was excited to see him grow. It has been a pleasure having him on my team. His kindness not only extends to our patients, but to his coworkers and YNHHS team members. He goes



[Read More](#)

Smilow Cancer Hospital has a new clinical trial available for patients age 18 and older diagnosed with breast cancer or lymphoma, who are scheduled to begin an intravenous chemotherapy regimen within the next eight weeks. Interested patients are asked to perform a 6-minute walking test on-site, wear an activity tracker, and have access to the internet via a mobile device or computer with the ability to upload tracker data and complete surveys.

*Medical Research Changes Lives*

You can change the course of cancer research. Scientists and doctors at Yale Cancer Center are working hard to bring you new cancer treatments. We need patients for clinical research to help bring discoveries from the laboratory to more people who need them. We hope you'll be one of them.

**Clinical Trial for:**  
Patients with lymphoma or breast cancer who will be starting systemic anti-cancer therapy within eight weeks

**Contact:**  
Yale Cancer Center Clinical Trials Office  
Lisa Torre  
lisa.torre@yale.edu



YaleNewHavenHealth  
Smilow Cancer Hospital

Yale CANCER CENTER  
A Comprehensive Cancer Center Designated by the National Cancer Institute

[Read More](#)

On Yale Cancer Answers, Palliative Care

Chaplain, Jane Jeuland, discussed spirituality and cancer as heard on her new podcast, "In the Midst of it All." Listen on Connecticut Public Radio or download our podcast from iTunes.



above and beyond daily and is proactive in closing the gap. We are so thankful to have him as part of the Smilow family. Our patients are in great hands with him.”

## #OOTB Recognition



Pictured with Dr. Amer Zeidan, **Anne Caldwell, RN**, and **Madelynn Bonfiglio**, and Daniel Moncayo (missing from photo) recently went above and beyond to support the Leukemia Clinical Research Team and clinical trial participants. Within the first two weeks of a high acuity, Phase I AML clinical trial opening at Yale Cancer Center, the team consented, screened, and began treatment for two participants. Notably, one of the participants was consented, screened, and treated in less than two days. Additionally, these were the first two participants enrolled study-wide for this clinical trial, achieving an important milestone. The complexity of this study required inpatient coordination, frequent sponsor communications, and weekend coverage, which Anne, Madelynn, and Daniel supported seamlessly. This extensive work occurred while maintaining the compliance and safety of their other clinical trial participants and assuming additional responsibilities to

bridge the team during staffing shortages. Anne, Madelyn, and Daniel approach challenges with a calm, team-focused mindset, and we are very grateful for their efforts and the opportunities it allows our patients. Thank you!

## Recent Publications

Peters GW, Talcott W, Peters NV, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park HS, Boffa D, Johung KL, Jethwa KR.

**Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer.**

*J Gastrointest Oncol.* 2023 Jun 30;14(3):1181-1192.

[Read More](#)



[Read More](#)


Recently, the staff at Smilow Cancer Hospital in Waterford were treated to a delicious summer picnic lunch from Chester's Barbecue in Groton as a thank you for the outstanding work they do supporting and caring for patients throughout the year!



[Read More](#)

Take a few minutes to read our Spring | Summer issue of Centerpoint Magazine.

This issue highlights the incredible story of Martha Atwood, who was diagnosed with Burkitt lymphoma and thrived through a challenging course of treatment. We also share new programs at Smilow Cancer Hospital to prioritize cancers in young adults and to provide exceptional palliative and prehabilitation care resources to our patients.



Wiegand A, Kastury R, Neogi A, Mani A, Bale A, Cox A.  
**FKBP14 kyphoscoliotic Ehlers-Danlos syndrome misdiagnosed as Larsen syndrome: a case report.**

*Cold Spring Harb Mol Case Stud.* 2023 Jul 11;9(3):a006281.

[Read More](#)

Lewin J, Schoenherr S, Seebass M, Lin M, Philpotts L, Etesami M, Butler R, Durand M, Heller S, Heacock L, Moy L, Tocino I, Westerhoff M.

**PACS-integrated machine learning breast density classifier: clinical validation.**

*Clin Imaging.* 2023 Sep;101:200-205.

[Read More](#)

Lee AI, Masselink LE, De Castro LM, Marshall AL, Connell NT, Dent GA, Fritz J, Homer M, Lucas TL, Naik RP, Nelson M, O'Connell CL, Rajasekhar A, Reynolds RJ, Sharma D, Smith M, Weeks LD, Erikson CE.

**Burnout in US hematologists and oncologists: impact of compensation models and advanced practice provider support.**

*Blood Adv.* 2023 Jul 11;7(13):3058-3068.

[Read More](#)

Grant MJ, Goldberg SB.

**Precise, pragmatic and inclusive: the modern era of oncology clinical trials.**

*Nat Med.* 2023 Aug;29(8):1908-1909.

[Read More](#)

Cao A, Cartmel B, Li FY, Gottlieb LT, Harrigan M, Ligibel JA, Gogoi R, Schwartz PE, Esserman DA, Irwin ML, Ferrucci LM.

**Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer: A Secondary Analysis of a Randomized Clinical Trial.**

*JAMA Netw Open.* 2023 Aug 1;6(8):e2326463.

[Read More](#)

Gu SX, Siddon AJ, Huntington SF, Jain D.

**Helicobacter pylori-negative mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach : A clinicopathologic analysis.**

*Am J Clin Pathol.* 2023 Aug 9:aqad088.

[Read More](#)

González IA, Torbenson M, Sharifai N, Byrnes K, Chatterjee D, Kakar S, Yeh MM, Wu TT, Zhang X, Jain D.

**Clinicopathologic characterization of hepatocellular adenomas in men: a multicenter experience.**

*Hum Pathol.* 2023 Aug;138:24-33.

[Read More](#)

Bakkila BF, Marks VA, Kerekes D, Kunstman JW, Salem RR, Billingsley KG, Ahuja N, Laurans M, Olino K, Khan SA.

**Impact of COVID-19 on the gastrointestinal surgical oncology patient population.**

*Heliyon.* 2023 Jul 20;9(8):e18459.

[Read More](#)

Kerekes D, Frey A, Bakkila B, Kunstman JW, Khan SA.

**Surgical treatment of stage IV gastroenteropancreatic neuroendocrine carcinoma: Experience and outcomes in the United States.**

*J Surg Oncol.* 2023 Jul 12.

[Read More](#)

Yan H, Talty R, Jain A, Cai Y, Zheng J, Shen X, Muca E, Paty PB, Bosenberg MW, Khan SA, Johnson CH.

**Discovery of decreased ferroptosis in male colorectal cancer patients with KRAS mutations.**

*Front Oncol.* 2023 Aug 23:1122222.

[Read More](#)



[Read More](#)

Courtney Gibson, MD, MS, FACS, is an Associate Professor of Surgery specializing in surgery of the thyroid, parathyroid and adrenal gland. Dr. Gibson recently gave a talk on parathyroid disease and tumors in recognition of Parathyroid Disease Awareness Month in July.

The presentation is available on our YouTube page for everyone interested in learning more.



[Read More](#)

Premier Subaru in Branford stopped by Smilow Cancer Hospital in North Haven to deliver 80 blankets for patients undergoing cancer treatment. The thick, soft blankets, accompanied by many messages of hope from Subaru personnel, are part of the partnership between the Leukemia & Lymphoma Society and Subaru Loves to Care supporting patients with cancer in Connecticut. The Premier Subaru team was met by several members of our clinical staff

who expressed their heartfelt appreciation for the thoughtful and generous gift for their patients.



Redox Biol. 2023 Jun;62:102699.

[Read More](#)

Kerekes DM, Frey AE, Bakkila BF, Johnson CH, Becher RD, Billingsley KG, Khan SA.

**Hepatopancreatobiliary malignancies: time to treatment matters.**

*J Gastrointest Oncol.* 2023 Apr 29;14(2):833-848.

[Read More](#)

Shah R, Boffa D, Khan S, Judson B.

**The Representation of Surgery in Oncology Clinical Trials: 2001 to 2022.**

*Ann Surg Oncol.* 2023 Aug 9.

[Read More](#)

Tsuboi, M., Herbst, R. S., John, T., Kato, T., Majem, M., Grohé, C., Wang, J., Goldman, J. W., Lu, S., Su, W. C., de Marinis, F., Shepherd, F. A., Lee, K. H., Le, N. T., Dechaphunkul, A., Kowalski, D., Poole, L., Bolanos, A., Rukazenzov, Y., Wu, Y. L.

**ADAURA Investigators (2023). Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.**

*The New England journal of medicine,* 389(2), 137–147.

[Read More](#)

Pusztai L.

**Systemic Staging of Locally Advanced Breast Cancer: How Hard to Look?.**

*Journal of clinical oncology : official journal of the American Society of Clinical Oncology,* 41(23), 3891–3894.

[Read More](#)

Henske, E. P., Cheng, L., Hakimi, A. A., Choueiri, T. K., & Braun, D. A.

**Chromophobe renal cell carcinoma.**

*Cancer cell,* S1535-6108(23)00246-5.

[Read More](#)

Richman, I. B., Long, J. B., Soulos, P. R., Wang, S. Y., & Gross, C. P.

**Estimating Breast Cancer Overdiagnosis After Screening Mammography Among Older Women in the United States.**

*Annals of internal medicine,* 10.7326/M23-0133.

[Read More](#)

Sun, G., Dizon, D. S., Szczepanek, C. M., Petrylak, D. P., Sparks, D. B., Tangen, C., Lara, P. L. N., Jr, Thompson, I. M., Jr, & Blanke, C. D.

**Crisis of the Clinical Trials Staff Attrition After the COVID-19 Pandemic.**

*JCO oncology practice,* 19(8), 533–535.

[Read More](#)

de Miguel, F. J., Gentile, C., Feng, W. W., Silva, S. J., Sankar, A., Exposito, F., Cai, W. L., Melnick, M. A., Robles-Oteiza, C., Hinkley, M. M., Tsai, J. A., Hartley, A. V., Wei, J., Wurtz, A., Li, F., Toki, M. I., Rimm, D. L., Homer, R., Wilen, C. B., Xiao, A. Z., ... Politi, K. A.

**Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.**

*Cancer cell,* S1535-6108(23)00245-3.

[Read More](#)

Earland, N., Zhang, W., Usmani, A., Nene, A., Bacchiocchi, A., Chen, D. Y., Sznol, M., Halaban, R., Chaudhuri, A. A., & Newman, A. M.

**CD4 T cells and toxicity from immune checkpoint blockade.**

*Immunological reviews,* 10.1111/imr.13248.

[Read More](#)

Price, S. N., Palmer, A. M., Fucito, L. M., Graboyes, E. M., Baker, N. L., Rojewski, A. M., & Toll, B. A.

**Tobacco use and cancer-related symptom burden: Analysis of the US**




[Read More](#)

The Yale Cancer Center-Advanced Training Program for Physician-Scientists (YCC-ATPP), led by principal investigators Roy S. Herbst, MD, PhD, and Lieping Chen, MD, PhD, is a five-year, T32 training program that provides salary and research funds for four 3rd year Hematology/Medical Oncology fellows.

The goal of this program is to help the fellows develop the skills necessary to function independently, including the ability to design, initiate, and complete research projects, and to effectively write grants and manuscripts. It uniquely positions the Heme/MedOnc fellows to become independent clinical, translational, or basic cancer research leaders of tomorrow.

Pictured (left-right): David Su, MD (Surgery resident, T32 fellow), Roy S. Herbst, MD, PhD; Meina Wang, PhD; Curt Perry, MD, PhD (Heme/Onc Fellow, T32 fellow); Jessica Stempel, MD, FACP (Heme/Onc fellow, T32 fellow); and Benjamin Lu, MD (Heme/Onc fellow, T32 fellow).

Not pictured: Jeremy Jacox, MD, PhD (Heme/Onc fellow, T32 fellow), and Thejal Srikumar, MD (T32 fellow).



[Read More](#)

Congratulations to Anish Sharda, MD, MPH, Assistant Professor of Hematology, the 2023 recipient of the JH Milstone Grant. The JH

## Population Assessment of Tobacco and Health Study.

*Cancer*, 129(15), 2385–2394.

[Read More](#)

Sekeres, M. A., Kim, N., DeZern, A. E., Norsworthy, K. J., Garcia, J. S., de Claro, R. A., Theoret, M. R., Jen, E. Y., Ehrlich, L. A., Zeidan, A. M., & Komrokji, R. S.

## Considerations for Drug Development in Myelodysplastic Syndromes.

*Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(14), 2573–2579.

[Read More](#)

Sun, T., Gilani, S., Jain, D., & Cai, G.

## Cytomorphologic, immunophenotypical and molecular features of pancreatic acinar cell carcinoma.

*Diagnostic cytopathology*, 10.1002/dc.25196.

[Read More](#)

Sanft, T., Day, A., Ansbaugh, S., Armenian, S., Baker, K. S., Ballinger, T., Demark-Wahnefried, W., Dickinson, K., Fairman, N. P., Felciano, J., Flores, T. F., Friedman, D. L., Gabel, N. M., Goldman, M., Henry, N. L., Hill-Kayser, C., Hudson, M., Koura, D., Lee, K., McDonough, A. L., ... Freedman-Cass, D. A.

## NCCN Guidelines® Insights: Survivorship, Version 1.2023.

*Journal of the National Comprehensive Cancer Network : JNCCN*, 21(8), 792–803.

[Read More](#)

Vish, K. J., Stiegler, A. L., & Boggon, T. J.

## Diverse p120RasGAP interactions with doubly phosphorylated partners EphB4, p190RhoGAP and Dok1.

*The Journal of biological chemistry*, 105098.

[Read More](#)

Doroshov, D. B., Wei, W., Mehrotra, M., Sia, D., Eder, J. P., Bindra, R., Houldsworth, J., LoRusso, P., & Walther, Z.

## Platinum Sensitivity in IDH1/2 mutated Intrahepatic Cholangiocarcinoma: Not all "BRCAness" is Created Equal.

*Cancer investigation*, 1–11.

[Read More](#)

Wang, Q. L., Ma, C., Yuan, C., Shi, Q., Wolpin, B. M., Zhang, Y., Fuchs, C. S., Meyer, J., Zemla, T., Cheng, E., Kumthekar, P., Guthrie, K. A., Couture,

F., Kuebler, P., Kumar, P., Tan, B., Krishnamurthi, S., Goldberg, R. M., Venook, A., Blanke, C., ... Ng, K.

## Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance).

*Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(14), 2621–2630.

[Read More](#)

Cao, A., Cartmel, B., Li, F. Y., Gottlieb, L. T., Harrigan, M., Ligibel, J. A., Gogoi, R., Schwartz, P. E., Esserman, D. A., Irwin, M. L., & Ferrucci, L. M.

## Effect of Exercise on Chemotherapy-Induced Peripheral Neuropathy Among Patients Treated for Ovarian Cancer: A Secondary Analysis of a Randomized Clinical Trial.

*JAMA network open*, 6(8), e2326463.

[Read More](#)

Di, M., Long, J. B., Kothari, S. K., Sethi, T., Zeidan, A. M., Podoltsev, N. A., Shallis, R. M., Wang, R., Ma, X., & Huntington, S. F.

## Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.

*Haematologica*, 108(8), 2218–2223.

[Read More](#)

Milstone Fund awards an annual grant to support early-stage investigators and innovative research that improves understanding of bleeding, thrombosis, or thrombolysis.

Dr. J. Haskell Milstone was a Professor of Pathology at Yale from 1947-1977. He taught pathology and blood coagulation to a generation of medical students and residents and advocated strongly for better treatment for those with hemophilia. This annual fund honors Dr. Milstone's seminal work in coagulation and will continue to support generations of researchers.



[Read More](#)



@YouTube says it's now removing videos promoting cancer misinformation, which can deeply prey "on the hope of our patients who have cancer," explains @PamelaKunzMD in an interview with @wnpr.



Congratulations to Dr. George Goshua @GeorgeGoshuaMD on his appointment to the editorial board for @AnnalsofIM.



"When we radiate the pelvis for rectal cancer, there are several important organs there. Radiation is very focused, but you hit more than the tumor."



Tonight at 7:30pm on Yale Cancer Answers, speech pathologist, John Gerrity, discusses his role in caring for patients after a diagnosis of head and neck cancer and methods of restoring speech. Listen live @wnpr or download our podcast from @iTunes.



A new study from co-senior author @AminNassarMD

Malla, A. B., Yu, H., Farris, D., Kadimi, S., Lam, T. T., Cox, A. L., Smith, Z. D., & Lesch, B. J.

### **DOT1L bridges transcription and heterochromatin formation at mammalian pericentromeres.**

*EMBO reports*, 24(8), e56492.

**Read More**

El Zarif, T., Nassar, A. H., Pond, G. R., Zhuang, T. Z., Master, V., Nazha, B., Niglio, S., Simon, N., Hahn, A. W., Pettaway, C. A., Tu, S. M., Abdel-Wahab, N., Velev, M., Flippot, R., Buti, S., Maruzzo, M., Mitra, A., Gheeya, J., Yang, Y., Rodriguez, P. A., ... Sonpavde, G. P.

### **Safety and efficacy of immune checkpoint inhibitors in advanced penile cancer: report from the Global Society of Rare Genitourinary Tumors.**

*Journal of the National Cancer Institute*, djad155.

**Read More**

Exposito, F., Redrado, M., Houry, M., Hastings, K., Molero-Abraham, M., Lozano, T., Solorzano, J. L., Sanz-Ortega, J., Adradas, V., Amat, R., Redin, E., Leon, S., Legarra, N., Garcia, J., Serrano, D., Valencia, K., Robles-Oteiza, C., Foggetti, G., Otegui, N., Felip, E., Politi K., ... Calvo, A.

### **PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.**

*Cancer research*, 83(15), 2513–2526.

**Read More**

Schrank, T. P., Kothari, A., Weir, W. H., Stepp, W. H., Rehmani, H., Liu, X., Wang, X., Sewell, A., Li, X., Tasoulas, J., Kim, S., Yarbrough, G., Xie, Y., Flamand, Y., Marur, S., Hayward, M. C., Wu, D., Burtness, B., Anderson, K. S., Baldwin, A. S., ... Issaeva, N.

### **Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors.**

*Proceedings of the National Academy of Sciences of the United States of America*, 120(32), e2216532120.

**Read More**

Bhatia, S., Pappo, A. S., Acquazzino, M., Allen-Rhoades, W. A., Barnett, M., Borinstein, S. C., Casey, R., Choo, S., Chugh, R., Dinner, S., Ermoian, R., Fair, D., Federman, N., Folbrecht, J., Gandhi, S., Germann, J., Goldsby, R., Hayashi, R., Huang, A. Y., Huang, M. S., Lustberg M., ... Hang, L.

### **Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN**

#### **Clinical Practice Guidelines in Oncology.**

*Journal of the National Comprehensive Cancer Network : JNCCN*, 21(8), 851–880.

**Read More**

Moutafi, M., Koliou, G. A., Papaxoinis, G., Economopoulou, P., Kotsantis, I., Gkatzamanidou, M., Anastasiou, M., Pectasides, D., Kyrodimos, E., Delides, A., Giotakis, E., Papadimitriou, N. G., Panayiotides, I. G., Perisanidis, C., Fernandez, A. I., Xirou, V., Poullos, C., Gagari, E., Yaghoobi, V., Gavrielatou, N., ... Psyrris, A.

### **Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.**

*Cancer research communications*, 3(8), 1514–1523.

**Read More**

Horowitch, B., Lee, D. Y., Ding, M., Martinez-Morilla, S., Aung, T. N., Ouerghi, F., Wang, X., Wei, W., Damsky, W., Sznol, M., Kluger, H., Rimm, D. L., & Ishizuka, J. J.

### **Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.**

*Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(15), 2908–2918.

**Read More**

Shallis, R. M., Daver, N., Altman, J. K., Komrokji, R. S., Pollyea, D. A., Badar,

shares encouraging evidence that

#immunotherapy offers clinical benefits for a subset of patients with advanced penile squamous cell carcinoma



Congratulations to Seth Herzon, PhD, the inaugural recipient of the A.V. Rama Rao Award given by the Council of the Chemical Research Society of India (CRSI) @ChemResSocIndia.



Patients w/stage IV#gastriccancer limited to nonregional lymph nodes exhibited a better prognosis than mets to a single organ, suggesting an opportunity to introduce M1 staging subclassifications.



The 2023 SNO/ASCO CNS Cancer Conference starts tomorrow, co-chaired by Sarah Goldberg, MD, MPH, with the keynote address presented by Don Nguyen, PhD, BS.



#Clinicaltrials using neoadjuvant #immunotherapy for #earlyTNBC were reviewed to learn more about next-gen challenges to improve outcomes + the potential of the #microbiome.



.@David\_Leffell shares how learning from the success of #smokingprevention, a comprehensive + unified #sunprotection policy can be developed to greatly the risks associated w/excessive sun exposure.



"The findings ... emphasize the need for a careful evaluation of the benefits + harms of screening older women (for #breastcancer)," says a study from @llanaRichman, @cpgyale, @shiyijwang, et al.



Incorporating aerobic exercise can improve #CIPN neuropathy in women treated for #ovariancancer according to a study from @anlan\_cao with Drs. Melinda Irwin @mirwin\_yale and Leah Ferrucci.



Dr. Michael Chiorazzi + colleagues developed a technique to fully reconstitute a person's immune system in a mouse, enabling researchers to study individual differences in #cancer progression

T., Bewersdorf, J. P., Bhatt, V. R., de Botton, S., de la Fuente Burguera, A., Carraway, H. E., Desai, P., Dillon, R., Duployez, N., El Chaer, F., Fathi, A. T., Freeman, S. D., Gojo, I., Grunwald, M. R., Jonas, B. A., ... Zeidan, A. M.

### **Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts.**

*The Lancet. Haematology*, S2352-3026(23)00159-X.

[Read More](#)

Micevic, G., Daniels, A., Flem-Karlsen, K., Park, K., Talty, R., McGeary, M., Mirza, H., Blackburn, H. N., Sefik, E., Cheung, J. F., Hornick, N. I., Aizenbud, L., Joshi, N. S., Kluger, H., Iwasaki, A., Bosenberg, M. W., & Flavell, R. A.

### **IL-7R licenses a population of epigenetically poised memory CD8<sup>+</sup> T cells with superior antitumor efficacy that are critical for melanoma memory.**

*Proceedings of the National Academy of Sciences of the United States of America*, 120(30), e2304319120.

[Read More](#)

LoRusso, P., Yamamoto, N., Patel, M. R., Laurie, S. A., Bauer, T. M., Geng, J., Davenport, T., Teufel, M., Li, J., Lahmar, M., & Gounder, M. M.

### **The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study.**

*Cancer discovery*, 13(8), 1802–1813.

[Read More](#)

Garralda, E., Schram, A. M., Bedard, P. L., Schwartz, G. K., Yuen, E., McNeely, S. C., Ribeiro, S., Cunningham, J., Wang, Y., Urnuela, A., Xu, X., & LoRusso, P.

### **A Phase I Dose-Escalation Study of LY3405105, a Covalent Inhibitor of Cyclin-Dependent Kinase 7, Administered to Patients With Advanced Solid Tumors.**

*The oncologist*, oyad215.

[Read More](#)

Bricoune, O., Kareem, S. S., Wallace, G., Iacono, D. P., Macaulay, R., Etame, A., Pina, Y., Robinson, T. J., & Mokhtari, S.

### **Epstein-Barr virus associated primary central nervous system lymphoma in an immunosuppressed patient with a comorbid autoimmune disorder: A case report.**

*Experimental and therapeutic medicine*, 26(2), 410.

[Read More](#)

## **Funding and Award Opportunities**

### **DoD Melanoma Research Program Funding Opportunities**

The FY23 Defense Appropriations Act provides funding for the Melanoma Research Program (MRP) to support innovative, high-impact melanoma research.

- **Melanoma Academy Scholar Award:** to develop a network of successful, highly DOD FY23 Melanoma Academy Scholar Award 5 productive melanoma researchers in a collaborative research and career development environment.  
**Pre-Application Deadline:** August 31, 2023
- **Mid-Career Accelerator Award:** to support investigators who have laid the foundation for becoming leaders in the melanoma field and who intend to advance the state of the science in melanoma.  
**Pre-Application Deadline:** August 31, 2023
- **Team Science Award:** to bring together investigators from divergent disciplines to achieve innovations and advancements in melanoma research and/or patient care that could not be achieved by any one investigator working independently.  
**Pre-Application Deadline:** August 31, 2023
- **Focused Program Award – Rare Melanomas:** to support a multidisciplinary research program of at least two, but not more than three, distinct but complementary projects addressing an overarching

+ treatment response.



"This study has revealed a new vulnerability of a subset of lung

#adenocarcinomas that have become resistant to standard-of-care targeted therapies," said Dr. Katerina Politi @politikaterina.

## **Calendar**

### **Yale Cancer Answers**

**August 20, 7:30 PM**

**WNPR 90.5**

*Advanced Techniques in Breast Surgery*

Tristen Park, MD

[Learn More](#)

### **Multi-Disciplinary Portal Hypertension and Vascular Liver Disorders Conference**

**August 22, 7:30 AM**

**Location TBA**

Todd Schlachter, MD

[Learn More](#)

### **Yale School of Medicine Biorepository Open Information Session**

**August 22, 1:00 PM**

**Zoom**

Chen Liu, MD, PhD | Wade Schulz, MD

[Learn More](#)

### **Yale Cancer Center and Smilow Cancer Hospital Town Hall**

**August 23, 5:00 PM**

**Zoom**

Kevin Billingsley, MD, MBA | Kim Slusser, RN | Robert Bona, MD | Paula Pike, RN, MBA | Christin Knowlton, MD, MA | Sharlene Hench | Ian Krop, MD, PhD | Alyssa Gateman, MPH

[Learn More](#)

### **Therapeutic Radiology Grand Rounds**

**August 24, 9:00 AM**

**35 Park Street, North Pavilion LL505**

*Theranostics and Precision Medicine*

Gabriela Spilberg, MD

[Learn More](#)

### **Yale Cancer Answers**

**August 27; 7:30PM**

**WNPR**

*Stereotactic Radiosurgery for Lung Cancer*

three, distinct but complementary projects addressing an overarching question relevant to rare melanomas

**Pre-Application Deadline:** August 31, 2023

[Read More](#)

### Hyundai Bridge2K Award for NIH K Award Applicants

The purpose of the Hyundai Bridge2K Award is to provide seed funding to support the resubmission efforts of strong pediatric cancer-focused grant applications that narrowly missed the pay line at national funding agencies. Ideal candidates are those with NIH K award applications (e.g., K08, K23) that were scored.

**Application Deadline:** August 31, 2023

[Read More](#)

### Limited Competition: Collaborative Partnership to Advance Global Health Research (U01 Clinical Trial Not Allowed)

The goal of this NOFO is to develop, establish, implement, and maintain a successful collaborative partnership to advance NIH priorities, support NIH collaboration on global health, and advance biomedical research internationally. This program will support a partnership between the NIH and the recipient(s) with the commitment and capacity to help extend NIH research-related programs worldwide.

**Application Deadline:** September 1, 2023

[Read More](#)

### Advancing Cancer Control Equity Research Through Transformative Solutions (U19/U24)

This Notice of Funding Opportunity (NOFO) invites proposals for research centers to advance cancer control equity by stimulating community-engaged, multilevel research interventions that address the impact of social determinants of health (SDOH) on adverse cancer control outcomes.

**Application Deadline:** September 14, 2023

[Read More](#)

### Gabrielle's Angel Foundation for Cancer Research 2023 Medical Research Awards

Identify two outstanding junior faculty members – one who is conducting

mainstream or conventional research and one who is conducting complementary or integrative research – who would be willing to complete and submit a grant application for review. Gabrielle's Angel Foundation remains committed to funding innovative, translational proposals and to supporting promising independent early-career investigators, rather than well-established, senior scientists.

**Application Deadline:** September 15, 2023

[Read More](#)

### The Leukemia & Lymphoma Society's Equity in Access Research Program

Through this program, LLS aims to generate new evidence that can guide policy reform and changes in healthcare practice, in order to mitigate the impact of social, economic and environmental disadvantages and reduce barriers to care.

**Letter of Intent Due:** September 15, 2023

[Read More](#)

### DoD Kidney Cancer Research Program

KCRP supports research of exceptional scientific merit in kidney cancer.

- Academy of Kidney Cancer Investigators Early-Career Scholar Award - Preproposal Due: September 15, 2023
- Clinical Trial Award - Preproposal Due: September 15, 2023
- Idea Development Award - Preproposal Due: September 15, 2023
- Nurse-Initiated Research Award Preproposal Due: September 15, 2023
- Translational Research Partnership Award - Preproposal Due: September 15, 2023

[Read More](#)

Nadine Housri, MD

[Learn More](#)

### Yale Cancer Answers

**September 3; 7:30PM**

WNPR

*The Role of a Hospitalist in Oncology Care*

Jensa Morris, MD and Sarach Schellhorn, MD

[Learn More](#)

### Yale Center for Molecular and Systems Metabolism (YMSM)

**September 5, 11:00 AM**

**Brady Auditorium; 310 Center Street, B131**

*In Search of the Holy Grail: Cardioplipin*

*Remodeling by ALCAT1 Controls the*

*Mitochondrial Aging Clock*

Yuguang (Roger) Shi, PhD

[Learn More](#)

### Center for GI Cancers Seminar Series 2023-2024

**September 7, 4:15 PM**

**Location and Speaker TBA**

[Learn More](#)

### Yale Eye Center Grand Rounds

**September 8, 7:00 AM**

**Location TBA**

*Mobilizing Lymphatics in Immune Privileged Spaces*

Eric Hoyeon Song, MD, PhD

[Learn More](#)

### Surgery Grand Rounds

**September 8, 7:30 AM**

**FMP Auditorium**

*"State of the Department"*

Nita Ahuja, MD, MBA, FACS

[Learn More](#)



### Share your news!

Please submit your recent publications, awards, and grant announcements to:

**Renee Gaudette**

Director, Public Affairs and Communications

### **NIH Institutional Excellence in Diversity, Equity, Inclusion, and Accessibility in Biomedical and Behavioral Research Prize Competition**

The prize competition goals are as follows:

1. To recognize and reward institutions whose biomedical, social, and behavioral science schools, departments, centers, or divisions have identified gaps with respect to diversity, equity, inclusion, and accessibility (DEIA) and have designed, implemented, and evaluated interventions to address these gaps to achieve sustained improvement in DEIA within their faculty, postdoctoral scholars, and student bodies.
2. To identify effective practices for enhancing DEIA within faculty, postdoctoral scholars, and student bodies that are feasible and can be disseminated for adoption by other institutions.

**Application Deadline:** September 26, 2023

**Read More**

### **The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clinical Trial Optional)**

This NOFO invites applications to participate as Core Clinical Centers and Consortia in the BMT CTN. Core Clinical Centers and Consortia are expected to support and conduct multi-site trials to compare novel treatment approaches and management strategies for children and adults undergoing hematopoietic stem cell transplantation (HCT) for non-malignant and malignant blood diseases, either alone or in combination with novel adoptive cell-based therapies.

**Application Deadline:** October 2, 2023

**Read More**

### **The Blood and Marrow Transplant Clinical Trials Network - Data Coordinating Center (U24)**

This NOFO invites applications to participate as the Data Coordinating Center (DCC) for the BMT CTN. The overall goals are to identify and address gaps in HCT and adoptive cell therapy outcomes for blood diseases; rapidly disseminate study results to improve the scientific basis of the therapies being studied; provide a platform to train emerging clinical trial investigators; build a biorepository for future research that includes

specimens linked to clinical data and outcomes from patients with non-malignant blood diseases who receive these therapies; and ultimately improve the life and quality of life for patients with blood diseases who receive HCT or adoptive cell therapies.

**Application Deadline:** October 2, 2023

**Read More**

### **Charles H. Hood Foundation Child Health Research Awards Program**

The intent of the Child Health Research Awards Program is to support newly independent faculty, provide the opportunity to demonstrate creativity, and assist in the transition to other sources of research funding.

**Application Deadline:** October 4, 2023

**Read More**

### **Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01)**

This NOFO supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the NOFO solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs.

**Application Deadline:** October 13, 2023

**Read More**

### **Leveraging Social Networks to Promote Widespread Individual Behavior Change (R01)**

The purpose of this NOFO is to invite basic observational or experimental behavioral and/or social science R01 applications that test how intrapersonal and interpersonal mechanisms of behavior change interact with, influence, or are influenced by characteristics of social networks, with implications for

health. Research supported through this NOFO will examine at least two levels of analysis: interpersonal processes and social network characteristics.

**Application Deadline:** November 3, 2023

**Read More**

Yale Cancer Center | 333 Cedar Street, New Haven, CT 06520

[Unsubscribe renee.gaudette@yale.edu](#)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by renee.gaudette@yale.edu powered by



Try email marketing for free today!